Engaging patient stakeholders early in the drug development process

Portrait of an immune cell the culprit behind many immune-mediated toxicities

As part of our role in the IMI project imSAVAR, we along with other partners convened a patient stakeholder workshop.

The focus was on the patient perspective on preclinical safety testing. This was a challenging topic. When we asked around no one could give us an example where the patient perspective was used in such an early phase of the drug development process. We forged ahead anyway.

The first remarkable outcome was that there are a number of patient stakeholder organizations that are very passionate about the topic of being able to predict the toxicity of immune system modulating therapies.

The second remarkable outcome was that patients often have to decide between different therapeutic options. When that happens, having more knowledge about the likelihood of experiencing a particular type of adverse outcome. You can read a summary of the workshop and see the recording here.

We have developed some accelerant projects as a means to concretely engage on some of the insights that emerged in the workshop. If you want to get involved in some of these join the imSAVAR stakeholder community.

At BioSci Consulting we are passionate about innovating ways to engage patient stakeholders in life sciences and healthcare collaborative innovation. If you share this passion and are trying to find ways to engage patient stakeholders get in touch.